Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 5 (2026)
International Multidisciplinary Journal for Research & Development

Articles

THE EFFECT OF EMPAGLIFLOZIN ON CARDIAC FUNCTIONAL STATUS IN CHRONIC HEART FAILURE

Published 2026-05-10

  • Hikmatov Azam Asatullayevich, Boboyev Nasimjon Malikovich, Eshonqulov Sardor Sindarovich

Hikmatov Azam Asatullayevich, Boboyev Nasimjon Malikovich, Eshonqulov Sardor Sindarovich
National Medical Center, Tashkent, Uzbekistan

Abstract

This article presents a comparative study of the effects of various standard treatment regimens on intracardiac hemodynamics and N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure, who were divided into three groups for observation. A highly significant increase in the left ventricular end-diastolic dimension, diastolic volume, and ejection fraction was detected in the third group of patients. This confirms the high cardioprotective effect of sacubitril/valsartan and empagliflozin.

Keywords

chronic heart failure, N-terminal pro-B-type natriuretic peptide, sacubitril/valsartan, empagliflozin.

PDF

References

  1. Alzahrani, S., Alosaimi, M., Malibarey, W. M., Alhumaidi, A. A.,Alhawaj, A. H., Alsulami, N. J., Alsharari, A. S., Alyami,A. A., Alkhateeb, Z. A., Alqarni, S. M. et al. (2019). Saudi Family Physicians' Knowledge of Secondary Prevention of Heart Disease: A National Assessment Survey. Archieves of Pharmacy Practice, 10 (4), 54-60.
  2. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
  3. Bayliss E. A. [et al.] Description of barriers to self-care by per- sons with comorbid chronic diseases // Annals of Family Medicine. – 2003. – Vol. 1, No 1. – P. 15–21.
  4. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135 (10):e146-e603. doi: 10.1161/CIR.0000000000000485.
  5. Bhatt A.S., Ambrosy A.P., Dunning A., DeVore A.D., Butler J., Reed S., Voors A., Starling R., Armstrong P.W., Ezekowitz J.A., Metra M., Hernandez A.F., O'Connor C.M., Mentz R.J. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. Eur J Heart Fail. 2020 Jun;22 (6):1022-1031.
  6. Bui, A. L., Horwich, T. B., & Fonarow, G. C. (2011). Epidemiology and risk profile of heart failure. Nature Reviews. Cardiology, 8 (1), 30-41.
  7. Davis M.E., Richards A.M., Nicholls M.G., Yandle T.G., Frampton C.M., Troughton R.W. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006; 113 (7): 977–985.
  8. Eisenstein E.L., Nelson C.L., Simon T.A., Smitten A.L., Lapuerta P., Mark D.B. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects with Heart Failure. Am Heart J 2002; 143 (6): 1112–1117.
  9. Groenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020). Epidemiology of heart failure. European Journal of Heart Failure, 22 (8), 1342-1356.
  10. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc. 2019 Oct 15;8 (20):e013389. doi: 10.1161/JAHA.119.013389.
  11. Permadi, A. W., Hartono, S., Wahjuni, E. S., & Lestari, N. K. D. (2020). The Combination of Physical Exercise Programs in Patients with Heart Failure. International Journal of Pharmaceutical and Phytopharmacological Research, 10 (1), 22-28.
  12. Reibis R., Jannowitz C., Halle M., Pittrow D., Gitt A., Völler H. Management and outcomes of patients with reduced ejection fraction after acute myocardial infarction in cardiac rehabilitation centers. Curr Med Res Opin 2015; 31 (2): 211–219.
  13. Richards A.M. Variability of NT-proBNP levels in heart failure: implications for clinical application. Heart 2007; 93 (8): 899–900.
  14. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tscho'pe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 May;20 (5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8. PMID: 29520964.
  15. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol. 2011 Jan;57 (1):8-17.
  16. Tang S., Peng D., Hu Y., Chen J. Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Eur Rev Med Pharmacol Sci 2015; 19 (5): 759–766.
  17. Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N. et al. (2021). Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association. Circulation. 143 (8):e254-e743.
  18. Batyushin M.M., Vrublevskaya N.S. Klinicheskiye proyavleniya porazheniya pochek pri khronicheskoy serdechnoy nedostatochnosti [Clinical manifestations of kidney damage in chronic heart failure]. Nefrologiya. 2010;14 (4):27-30.
  19. Berezikova, Yekaterina Nikolayevna, Pustovetova, Mariya Gennadevna, Shilov, Sergey Nikolayevich, Yefremov, Anatoliy Vasilevich, Teplyakov, Aleksandr Trofimovich, Safronov, Igor Dmitriyevich, & Samsonova, Yelena Nikolayevna (2014). The prognostic role of the metabolic risk factor (hyperhomocysteinemia) in the development of chronic heart failure. *Patologiya krovoobrashcheniya i kardiokhirurgiya* [Pathology of Blood Circulation and Cardiac Surgery], 18 (1), 20-25.
  20. Vasyuk, Yu. A. (2003). Possibilities and limitations of echocardiographic examination in assessing left ventricular remodeling in CHF. *Serdechnaya nedostatochnost'* [Heart Failure], 4 (2), 107-110.
  21. Tereshchenko, S. N. (Ed.). (2007). *Nekotorye nereshennye voprosy khronicheskoy serdechnoy nedostatochnosti* [Some Unresolved Issues of Chronic Heart Failure]. Moscow.
  22. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., et al. (2017). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Rossiyskiy kardiologicheskiy zhurnal* [Russian Journal of Cardiology], 1 (141), 7–81. 2017;
  23. Preobrazhensky, D. V. (2019). Anemia in chronic heart failure: a view on pathogenesis and methods of correction. *Kardiologiya i Serdechno-Sosudistaya Khirurgiya* [Cardiology and Cardiovascular Surgery], No. 2 (157).
  24. Storozhakov, G. I., Gendlin, G. E., & Reznik, E. V. (2009). The heart aches – the kidneys suffer: cardiorenal syndrome in chronic heart failure. *Lechebnoye delo* [Medical Business], No. 1, pp. 27-36.

Downloads

Download data is not yet available.